We are live on
!
Find out more
DCM
DAFNA Capital Management Portfolio holdings
AUM
$524M
1-Year Est. Return
164.42%
This Fund
S&P 500
This Quarter
Est. Return
+10.05%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$206M
AUM Growth
+$19.9M
(+11%)
Cap. Flow
-$6.78M
Cap. Flow
% of AUM
-3.3%
Top 10 Holdings %
Top 10 Hldgs %
45.09%
Holding
85
New
12
Increased
15
Reduced
25
Closed
10
Avg Time Held
5.9
quarters
Top 10 Avg Time Held
5.2
quarters
Top 20 Avg Time Held
5.2
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sage Therapeutics
SAGE
|
+$11.1M |
| 2 |
Stereotaxis
STXS
|
+$8.18M |
| 3 |
Akebia Therapeutics
AKBA
|
+$6.64M |
| 4 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$4.93M |
| 5 |
LMNX
Luminex Corp
LMNX
|
+$4.14M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
LOXO
Loxo Oncology, Inc
LOXO
|
+$12.2M |
| 2 |
BeOne Medicines Ltd
ONC
|
+$7.32M |
| 3 |
argenx
ARGX
|
+$2.81M |
| 4 |
Voyager Therapeutics
VYGR
|
+$2.61M |
| 5 |
Ascendis Pharma A/S
ASND
|
+$2.55M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.6% |
| 2 | Miscellaneous | 6.59% |
| 3 | Financials | 0.81% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
| $20.9M | 10.19% |
181,537
-114,463
| -39% | -$12.2M |
2015 Q2
11 quarters
|
|
|
2
DELISTED
Sage Therapeutics
SAGE
| $15.1M | 7.37% |
94,000
+65,200
| +226% | +$11.1M |
2017 Q4
1 quarter
|
|
|
3
Stereotaxis
STXS
$104M
| $9.1M | 4.43% |
13,680,554
+12,307,692
| +896% | +$8.18M |
2013 Q2
19 quarters
|
|
4
DELISTED
Blueprint Medicines
BPMC
| $8.13M | 3.96% |
88,691
-12,000
| -12% | -$1.03M |
2016 Q4
5 quarters
|
|
5
AtriCure
ATRC
$2.92B
| $7.99M | 3.88% |
389,145
| – | – |
2013 Q2
19 quarters
|
|
|
NXTM
6
DELISTED
NxStage Medical Inc.
NXTM
| $7.61M | 3.7% |
306,119
+90,000
| +42% | +$2.19M |
2013 Q2
19 quarters
|
|
|
AERI
7
DELISTED
Aerie Pharmaceuticals
AERI
| $7.2M | 3.5% |
132,770
+16,000
| +14% | +$895K |
2014 Q3
14 quarters
|
|
|
8
Akebia Therapeutics
AKBA
$205M
| $5.82M | 2.83% |
610,738
+475,000
| +350% | +$6.64M |
2017 Q1
4 quarters
|
|
9
DexCom
DXCM
$31.8B
| $5.56M | 2.71% |
300,000
-32,000
| -10% | -$473K |
2017 Q3
2 quarters
|
|
|
10
Ascendis Pharma A/S
ASND
$14.8B
| $5.18M | 2.52% |
79,245
-45,394
| -36% | -$2.55M |
2015 Q1
12 quarters
|
|
|
ALDR
11
DELISTED
Alder Biopharmaceuticals
ALDR
| $5.03M | 2.45% |
396,013
+50,000
| +14% | +$723K |
2015 Q3
10 quarters
|
|
|
ARNA
12
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $5.01M | 2.44% |
+126,742
| New | +$4.93M |
2018 Q1
0 quarters
|
|
|
LMNX
13
DELISTED
Luminex Corp
LMNX
| $4.79M | 2.33% |
227,500
+202,500
| +810% | +$4.14M |
2017 Q3
2 quarters
|
|
|
14
argenx
ARGX
$52B
| $4.68M | 2.27% |
58,130
-37,266
| -39% | -$2.81M |
2017 Q2
3 quarters
|
|
15
BioCryst Pharmaceuticals
BCRX
$2.07B
| $4.65M | 2.26% |
974,652
-218,576
| -18% | -$1.12M |
2016 Q4
5 quarters
|
|
16
Neurocrine Biosciences
NBIX
$13.8B
| $4.52M | 2.2% |
54,508
| – | – |
2016 Q1
8 quarters
|
|
17
DELISTED
Cymabay Therapeutics
CBAY
| $4.21M | 2.05% |
323,843
-37,321
| -10% | -$464K |
2017 Q1
4 quarters
|
|
|
IMMU
18
DELISTED
Immunomedics Inc
IMMU
| $4.1M | 2% |
280,900
-23,100
| -8% | -$377K |
2016 Q2
7 quarters
|
|
19
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.9B
| $3.95M | 1.92% |
39,609
| – | – |
2015 Q3
10 quarters
|
|
|
ZGNX
20
DELISTED
Zogenix, Inc.
ZGNX
| $3.77M | 1.84% |
94,264
-39,883
| -30% | -$1.58M |
2015 Q1
12 quarters
|
|
21
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $3.49M | 1.7% |
33,267
| – | – |
2017 Q4
1 quarter
|
|
|
ACHN
22
DELISTED
Achillion Pharmaceuticals
ACHN
| $3.22M | 1.57% |
868,272
-80,000
| -8% | -$262K |
2014 Q3
14 quarters
|
|
23
Rigel Pharmaceuticals
RIGL
$887M
| $3.19M | 1.55% |
90,193
-8,155
| -8% | -$326K |
2017 Q1
4 quarters
|
|
24
Insulet
PODD
$9.45B
| $2.82M | 1.37% |
32,484
| – | – |
2013 Q2
19 quarters
|
|
25
iShares Biotechnology ETF
IBB
$10.4B
| $2.79M | 1.36% |
26,100
| – | – |
2016 Q4
5 quarters
|
|
Similar funds
4WM
BB
A
HW
DAM
SDWIA
SCA
BHPW
DAFNA Capital Management's Q1 2018 Portfolio in Review
As of Q1 2018, DAFNA Capital Management held 85 positions worth $206M, up 11% from $186M the previous quarter. Its ten largest holdings account for 45% of the portfolio.
DAFNA Capital Management withdrew a net $6.78M in Q1 2018, closing 10 positions and reducing 25 holdings. Its most notable exit was Voyager Therapeutics, an estimated $2.61M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 93% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, DAFNA Capital Management opened a new position in Arena Pharmaceuticals Inc worth $5.01M.
- DAFNA Capital Management's largest Q1 2018 buy was Arena Pharmaceuticals Inc: 126,742 shares worth $5.01M.
- DAFNA Capital Management added most to Sage Therapeutics in Q1 2018, an estimated $11.1M increase.
- DAFNA Capital Management's biggest Q1 2018 reduction was Loxo Oncology, Inc, cutting an estimated $12.2M.
- DAFNA Capital Management fully exited Voyager Therapeutics in Q1 2018, selling an estimated $2.61M.
- DAFNA Capital Management's ten largest holdings make up 45% of its $206M portfolio in Q1 2018.
- DAFNA Capital Management opened 12 new positions and closed 10 in Q1 2018.
- DAFNA Capital Management's portfolio value rose 11% quarter-over-quarter to $206M.
Based on DAFNA Capital Management's 13F filing for Q1 2018, filed 15 May 2018.